Exclusive-Zeekr investors criticise Geely's $2.2 billion take-private bid as inadequate, say sources
HONG KONG/SHANGHAI (Reuters) -China's Geely is undervaluing its premium electric car unit Zeekr with the $2.2 billion take-private offer it has made, five early investors in Zeekr have written to its board, according to three sources with direct knowledge of the matter.
The investors, including Contemporary Amperex Technology Co Ltd (CATL), Intel Capital and Boyu Capital, who invested in Zeekr's maiden fundraising round, have sent two letters written jointly to the company and a special committee formed to assess the offer, saying that the privatisation price was too low to reflect the fair value of Zeekr, the sources told Reuters.
Geely, one of China's most globally known automakers due to its purchase of foreign marquees such as Volvo and Proton, offered on May 7 to privatise Zeekr, saying it wanted to fully merge Zeekr into Geely Auto.
Geely Auto owns about two-thirds of Zeekr. Both companies sit under the umbrella of their unlisted parent, Geely Holding. Geely founder and chairman Eric Li also chairs the Zeekr board.
The move surprised the market and the auto industry, given how it came just a year after it took the EV brand public in the United States.
It has also raised questions on the prospects of two other Geely units preparing for Hong Kong listings, including ride-hailing firm CaoCao Inc, and raised questions over whether Geely might delist its other U.S.-listed units such as Polestar.
The other two investors who wrote the letters were Bilibili and Cathay Fortune Corp.
A spokesperson for Geely said that talks with Zeekr's special committee were ongoing.
Zeekr, CATL, Intel Capital, Boyu Capital, Cathay Fortune did not respond to requests for comment. Bilibili declined to comment.
The offer is non-binding according to Geely Auto's filing. A binding commitment will only arise upon the execution of definitive agreements, subject to the terms and conditions, it said.
IMPROVING THE STRATEGIC FOCUS
Li has pivoted Geely away from its history of aggressive acquisitions to streamlining operations and cutting costs amid a brutal price war in China's auto market, the world's biggest.
He launched last year a campaign to improve the group's strategic focus and eliminate internal competition, which has so far involved it restructuring its brands into two units and merging some teams that were working on digital cockpit technology.
Zeekr is now viewed as Geely's best asset - sales of the brand reached 41,403 units in the first quarter of this year with six models, increasing 25% from a year ago and outselling BYD's premium brand Denza.
The five investors said in the first letter they sent last week that the privatisation price only valued Zeekr at $6.5 billion, much lower than peers such as Li Auto, Nio and Xpeng, according to the three sources.
They said Zeekr has a better cash flow and profitability prospects than these peers, and urged the deal should only proceed after obtaining the agreement of the majority of the "independent minority" shareholders.
Two of the sources said the investors sent a second letter this week, reiterating what they said in the first letter and urging the Zeekr special committee to carefully review and evaluate the offer.
The five investors took part in Zeekr's first external fundraising round of $500 million that valued it at $9 billion in 2021. At the time, they together held a 6% stake in the company.
A subsequent fundraising round valued the EV maker at $13 billion in 2023 but a year later it went public at a valuation of $5.5 billion on a fully diluted basis, less than half of the pre-IPO figure.
Two of the sources said Y2 Capital, an investor in Zeekr's IPO, had sent a similar letter voicing concerns to Geely's leadership. Y2 Capital did not respond to a request for comment.
Geely's offer of $25.66 per American Depository Share of Zeekr represented a 24% premium to its average share price over the four weeks prior to the offer announcement. The average premium paid in U.S. take-private deals has been about 40% since 2023, according to LSEG data.
Zeekr shares are now trading above the offer price and last closed at $26.59.
However, analysts said that Geely Auto may have sufficient votes to carry out the privatisation without the need for other shareholder approvals given its 65.7% stake in Zeekr.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Hegseth: Prepare for war to ensure Indo-Pacific peace
May 31 (UPI) -- The United States and its allies won't allow China to dominate the Indo-Pacific region, but do not seek war, Defense Secretary Pete Hegseth said Saturday morning in Singapore. He addressed regional concerns while speaking during the International Institute for Strategic Studies Shangri-La Dialogue event in Singapore. Hegseth said the Indo-Pacific region is the United States' "priority theater" and won't allow China to push the United States and its allies out of the region, the Department of Defense announced Friday in a news release. Instead, deterrence will be the primary tool by which the United States and its allies will counter any aggressive moves made by China, particularly in the South China Sea and against Taiwan. "As our allies share the burden, we can increase our focus on the Indo-Pacific," Hegseth said, adding that the region is the nation's "priority theater." He said the futures of the United States and its allies in the Indo-Pacific depend on each other. "We share a vision of peace and stability, of prosperity and security," Hegseth said, "and we are here to stay." Common sense and national interests with guide policy making in the region, while respecting mutual self-interests. President Donald Trump is working to get European nations to do more to increase their respective national security interests instead of largely relying on the United States. As European nations do more to protect themselves, Hegseth said the United States will be better able to focus on matters in the Indo-Pacific region and do more to thwart Chinese aggression. "This enables all of us to benefit from the peace and stability that comes with a lasting and strong American presence here in the Indo-Pacific," Hegseth said. That presence won't come at a cost for the nation's allies, though. "We are not here to pressure other countries to embrace and adopt our politics or ideology," Hegseth told the audience. "We are all sovereign nations." He said the United States does not "seek conflict with communist China." But the United States "will not be pushed out of this critical region," Hegseth added. "And we will not let our allies and partners be subordinated and intimidated." He said China's leaders are "preparing to use military force to alter the balance of power in the Indo-Pacific," including occupying Taiwan. Any move by China to take over Taiwan, which China has claimed as part of its sovereign state, would trigger "devastating consequences" for the region and the world, Hegseth told the audience. "The threat China poses is real, and it could be imminent," he said, adding that the United States and its allies must be prepared with "urgency and vigilance." If deterrence doesn't work and a fighting war is inevitable, "we are prepared to do what the Department of Defense does best: to fight and win decisively," Hegseth said. The best way to ensure peace is to prepare for war, "but we have to do this quickly," he said. "We have no time to waste."
Yahoo
an hour ago
- Yahoo
oneworld alliance Strengthens Leadership Team With Three Key Appointments
DELHI, India, May 31, 2025 /PRNewswire/ -- oneworld® alliance today continues to enhance its global capabilities and build a powerful go forward strategy with the appointment of three senior executives to its leadership team. Stephan Nagel has been named Vice President – Global Partnerships. A highly recognised expert in the airline industry with a strong record in Global Alliances, Airline Partnerships and Strategic Planning, Nagel brings in more than 25 years of experience in aviation. He has held high-profile roles in Qatar Airways, Air Berlin, Star Alliance and Lufthansa, where he was instrumental in forging and nurturing comprehensive network strategies, business transformation and industry-leading strategic partnerships that have significantly expanded the global reach and operational efficiency of the airlines he has served. He is a familiar face and a trusted voice in oneworld, having served on the oneworld Management Board for 10 years. In his new role, Nagel will be responsible for advancing strategic partnerships across the alliance, including member airlines and key technology and loyalty partners. Chris Kelly Singley has been appointed Vice President – Communications and Marketing. A highly respected communications executive with deep expertise in corporate reputation, stakeholder engagement and crisis management, Singley brings more than two decades of experience in the aviation and aerospace sectors. She has held senior roles at JetZero, Boeing, American Airlines and Delta Air Lines, leading high-profile campaigns and strategic initiatives spanning global media relations, employee engagement and CSR. At oneworld, Singley will lead the alliance's global communications and marketing strategies, shaping its narrative and amplifying its impact among customers, partners and stakeholders. Guido van Til has been named Vice President – Digital. A transformation leader with a strong track record across technology, customer experience, and digital innovation, van Til brings more than 25 years of experience in aviation and retail. He most recently supported top global brands including Rituals and Dyson through their digital transformation journeys, and previously spent more than 30 years at Air France-KLM, where he held several senior roles and reshaped the group's digital strategy, drove platform convergence, and spearheaded product development across all digital touchpoints. At oneworld, he will lead the alliance's digital strategy and delivery to ensure an integrated, customer-focused digital ecosystem. "Stephan, Chris and Guido are proven leaders with outstanding credentials and deep expertise across their respective fields. Each brings unique strengths to the alliance that will help shape the next chapter of growth and innovation for oneworld," said Nat Pieper, CEO of oneworld. "I'm delighted to welcome them to the team as we continue building on our 25-year legacy to deliver exceptional quality and service to our customers and partners around the world." For media queries, please contact press@ About oneworldoneworld brings together 14 world-class airlines – Alaska Airlines, American Airlines, British Airways, Cathay Pacific, Fiji Airways, Finnair, Iberia, Japan Airlines, Malaysia Airlines, Qantas, Qatar Airways, Royal Air Maroc, Royal Jordanian and SriLankan Airlines, and more than 20 of their affiliates. oneworld member airlines work together to consistently deliver a superior, seamless travel experience, with special rewards and privileges for its frequent flyers, including earning and redeeming miles and points across the entire alliance network, access to airport lounges, priority check-in and boarding, extra baggage allowances and more. Learn more about the the oneworld® alliance at Follow us on Facebook, Instagram, X and LinkedIn. View original content to download multimedia: SOURCE oneworld Management Company, Inc Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Breakthrough Clinical Data for LBL-024 in First-Line Treatment of Advanced EP-NEC Unveiled at 2025 ASCO Oral Session
NANJING, China, May 31, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") today announced the presentation of groundbreaking clinical data from a multicenter phase Ib/II clinical trial evaluating LBL-024, an anti-PD-L1/4-1BB bispecific antibody, in combination with etoposide plus platinum-based chemotherapy for treatment-naive patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC). The results were featured in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. ASCO is recognized as the world's most prestigious oncology conference, serving as a global stage for unveiling transformative scientific and clinical advancements. The Oral Sessions are highly competitive, served for studies demonstrating significant clinical relevance or scientific innovation. In 2025, ASCO received a record-breaking 7,775 abstract submissions, with 32 Chinese-led studies selected for oral presentation - among them, the LBL-024 trial (NCT06157827). The study, led by Professor Shen Lin of Peking University Cancer Hospital and conducted across multiple clinical centers, evaluates the efficacy and safety of LBL-024 combined with etoposide plus platinum-based chemotherapy as a first-line treatment for advanced EP-NEC. Robust Anti-Tumor Activity Observed with LBL-024 Plus Chemotherapy In 52 efficacy-evaluable patients, the overall response rate (ORR) across all dose levels was 75.0% and the disease control rate (DCR) was 92.3%, significantly outperforming historical ORR data (30%-55%) with chemotherapy alone. The 15 mg/kg in dose optimization demonstrated the strongest anti-tumor activity, achieving an ORR of 83.3% and a DCR of 100%. 57.7% (30/52) of the patients experienced >50% tumor shrinkage. As of April 15th, 2025, with a median follow-up of 8.2 months, progression-free survival (PFS) data remains immature, but trends indicate promising durability across all the dose groups. In the phase Ib dose escalation stage, no dose-limiting toxicities (DLTs) were observed. Most treatment-emergent adverse events (TEAEs) were Grade 1–2 and manageable, primarily associated with chemotherapy, including hematologic toxicity and nausea. No unexpected safety signals were identified. Leadership Perspectives Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated:" We are thrilled to share these exciting clinical data, which strongly support the advancement of LBL-024 into a pivotal phase III trial as a first-line treatment for EP-NEC. Our strategy prioritizes efficient development through single-arm registrational trial in underserved indications, while also maximizing value through broad indication expansion. LBL-024 received regulatory clearance in April 2024 to initiate a single-arm pivotal trial in China, marking the first 4-1BB targeted agent globally to reach this stage. With its expanded use now demonstrated in first-line settings and active studies in cancers such as SCLC and NSCLC, LBL-024 is poised to offer promising transformative therapeutic options for more cancer patients worldwide." Dr. Xiaoqiang Kang, Founder, Chairman and CEO of Leads Biolabs, added, "It is deeply encouraging to see LBL-024 featured consecutively in ASCO oral presentations. From target selection to molecular design, our R&D approach has focused on differentiated innovation to address pressing clinical challenges. The success of LBL-024 reflects our commitment to pioneering innovation at the source—breaking free from homogeneity to deliver genuinely impactful therapies. We remain dedicated to addressing unmet needs, advancing breakthrough therapeutics, and improving outcomes for patients across the globe." About LBL-024 LBL-024 is a potential first-in-class bispecific antibody simultaneously targeting PD-L1 and the co-stimulatory receptor 4-1BB. It is the first 4-1BB-targeting bispecific antibody globally to reach the single arm pivotal trial stage as a monotherapy and holds promise to become the first approved treatment specifically for extrapulmonary neuroendocrine carcinoma (EP-NEC), a malignancy with significant unmet medical need. Developed using Leads Biolabs' proprietary X-Body™ bispecific platform, LBL-024 features a 2:2 format with two binding domains each for PD-L1 and 4-1BB, and an optimized affinity ratio. This design allows LBL-024 to both reverse PD-L1–mediated immune suppression and selectively enhance T cell activation, resulting in potent, synergistic anti-tumor effects. In Phase I/II clinical trials in China, LBL-024 has demonstrated promising efficacy and a favorable safety profile in patients with advanced EP-NEC, both as monotherapy and in combination with chemotherapy. The lack of a standard of care in EP-NEC supports the pursuit of accelerated approval through a single-arm pivotal study. In recognition of its clinical potential, LBL-024 received Breakthrough Therapy Designation (BTD) from the National Medical Products Administration (NMPA) in China (October 2024), and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for neuroendocrine carcinoma (November 2024). Beyond NEC, LBL-024 has shown encouraging early activity in other tumor types, including small cell lung cancer (SCLC), ovarian cancer (OC), biliary tract cancer (BTC), and with strong potential for expansion into broader indications such as non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), and gastric cancer (GC). About Leads Biolabs Founded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology, autoimmune, and other severe diseases both in China and globally. We are a front-runner in next-generation immuno-oncology treatments with a differentiated pipeline of 12 innovative drug candidates, including six clinical-stage drug candidates, of which four lead products are among the top-tier clinically advanced candidates globally. We adopt a science-driven R&D approach and have successfully established comprehensive R&D capabilities spanning antibody discovery and engineering, in vivo and in vitro efficacy evaluation, as well as druggability assessment. We have also developed multiple proprietary technology platforms, including LeadsBodyTM platform (a CD3 T-cell engager platform), X-bodyTM platform (a 4-1BB engager platform), which serve as the cornerstone for our continued innovation and have been validated by the clinical outcomes of our bispecific antibody portfolios. We have established integrated capabilities across early discovery, translational medicine, clinical development, CMC and business development. The innovative nature and competitive strengths of our drug candidates, coupled with our global perspectives, proactive strategy, and efficient clinical validation, have made us an attractive partner for leading industry players and venture capitals. For more information, please visit View original content: SOURCE Leads Biolabs